- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Infant Bacterial Therapeutics AB (IBTb)
Infant Bacterial Therapeutics AB stock price live, this page displays ST IBTb stock exchange data. View the IBTb premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Infant Bacterial Therapeutics AB real time stock price chart below.
What Is the Infant Bacterial Therapeutics AB Stock Price Today?
The Infant Bacterial Therapeutics AB stock price today is 53.00.
What Is the Stock Symbol for Infant Bacterial Therapeutics AB?
The stock symbol for Infant Bacterial Therapeutics AB is ""IBTb.""
What Stock Exchange Does Infant Bacterial Therapeutics AB Trade On?
Infant Bacterial Therapeutics AB is listed and trades on the Stockholm stock exchange.
Is Infant Bacterial Therapeutics AB a Good Stock to Buy?
Determining whether Infant Bacterial Therapeutics AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IBTb quote. (ISIN: SE0008015259)
What Is the Infant Bacterial Therapeutics AB Stock Price Today?
The Infant Bacterial Therapeutics AB stock price today is 53.00.
What Is the Stock Symbol for Infant Bacterial Therapeutics AB?
The stock symbol for Infant Bacterial Therapeutics AB is ""IBTb.""
What Stock Exchange Does Infant Bacterial Therapeutics AB Trade On?
Infant Bacterial Therapeutics AB is listed and trades on the Stockholm stock exchange.
Is Infant Bacterial Therapeutics AB a Good Stock to Buy?
Determining whether Infant Bacterial Therapeutics AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IBTb quote. (ISIN: SE0008015259)
Stockholm
Currency in SEK
53.00
-0.20(-0.38%)
Closed·
Fair Value
An estimate of a Infant Bacterial Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.30
53.50
52 wk Range
21.70
105.00
IBTb Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IBTb is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Infant Bacterial Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.3053.50
52 wk Range
21.70105.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IBTb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Infant Bacterial Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Infant Bacterial Therapeutics AB Company Profile
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Compare IBTb to Peers and Sector
Metrics to compare | IBTb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIBTbPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | −3.0x | −0.6x | |
PEG Ratio | −0.25 | −0.03 | 0.00 | |
Price/Book | 5.3x | −1.1x | 2.6x | |
Price / LTM Sales | −713,985.3x | −233,855.2x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 37.4% | |
Fair Value Upside | Unlock | 0.0% | 4.5% | Unlock |
Earnings
Latest Release
Aug 20, 2025
EPS / Forecast
-1.42 / --
Revenue / Forecast
-- / --
FAQ
What Stock Exchange Does Infant Bacterial Therapeutics Trade On?
Infant Bacterial Therapeutics is listed and trades on the Stockholm Stock Exchange stock exchange.
What Is the Stock Symbol for Infant Bacterial Therapeutics?
The stock symbol for Infant Bacterial Therapeutics is "IBTb."
What Is the Infant Bacterial Therapeutics Market Cap?
As of today, Infant Bacterial Therapeutics market cap is 713.99M.
What Is Infant Bacterial Therapeutics's Earnings Per Share (TTM)?
The Infant Bacterial Therapeutics EPS (TTM) is -7.60.
From a Technical Analysis Perspective, Is IBTb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Infant Bacterial Therapeutics Stock Split?
Infant Bacterial Therapeutics has split 2 times.
How Many Employees Does Infant Bacterial Therapeutics Have?
Infant Bacterial Therapeutics has 8 employees.
What is the current trading status of Infant Bacterial Therapeutics (IBTb)?
As of 25 Aug 2025, Infant Bacterial Therapeutics (IBTb) is trading at a price of 53.00, with a previous close of 53.00. The stock has fluctuated within a day range of 52.30 to 53.50, while its 52-week range spans from 21.70 to 105.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.